title: Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight.
abstract: OBJECTIVE
  Data from solid tumor malignancies suggest that actual body weight (ABW) dosing improves overall outcomes. There is the potential to compromise efficacy when chemotherapy dosages are reduced, but the impact of dose adjustment on clinical response and toxicity in hematologic malignancies is unknown. The purpose of this study was to evaluate the outcomes of utilizing a percent of ABW for acute myeloid leukemia (AML) induction chemotherapy dosing.
  
  
  METHODS
  This retrospective, single-center study included 146 patients who received 7 + 3 induction (cytarabine and anthracycline) for treatment of AML. Study design evaluated the relationship between percentage of ABW dosing and complete response (CR) rates in patients newly diagnosed with AML.
  
  
  RESULTS
  Percentage of ABW dosing did not influence CR rates in patients undergoing induction chemotherapy for AML (p = 0.83); nor did it influence rate of death at 30 days or relapse at 6 months (p = 0.94). When comparing patients dosed at 90-100 % of ABW compared to <90 % ABW, CR rates were not significantly different in patients classified as poor risk (p = 0.907). All favorable risk category patients obtained CR.
  
  
  CONCLUSIONS
  Preemptive dose reductions for obesity did not influence CR rates for patients with AML undergoing induction chemotherapy and did not influence the composite endpoint of death at 30 days or disease relapse at 6 months.
authors.affiliation: Department of Pharmacy, The University of Kansas Hospital Cancer Center Pharmacy, 2330 Shawnee Mission Parkway, Mail Stop 5022, Westwood, KS, 66205, USA. wbray@kumc.edu.
authors.forename: Whitney M
authors.initials: WM
authors.lastname: Bray
authors.affiliation: Department of Pharmacy, University of Kansas School of Pharmacy, The University of Kansas Hospital Cancer Center Pharmacy, 2330 Shawnee Mission Parkway, Mail Stop 5022, Westwood, KS, 66205, USA. cbivona@kumc.edu.
authors.forename: Cory
authors.initials: C
authors.lastname: Bivona
authors.affiliation: Department of Pharmacy, University of Kansas School of Pharmacy, The University of Kansas Hospital Cancer Center Pharmacy, 2330 Shawnee Mission Parkway, Mail Stop 5022, Westwood, KS, 66205, USA. mrockey@kumc.edu.
authors.forename: Michelle
authors.initials: M
authors.lastname: Rockey
authors.affiliation: University of Kansas School of Pharmacy, The University of Kansas Hospital, 3901 Rainbow Blvd, Mail Stop 4047, Kansas City, KS, 66160, USA. dhenry@kumc.edu.
authors.forename: Dave
authors.initials: D
authors.lastname: Henry
authors.affiliation: University of Kansas School of Pharmacy, The University of Kansas Hospital, 3901 Rainbow Blvd, Mail Stop 4047, Kansas City, KS, 66160, USA. dgrauer@kumc.edu.
authors.forename: Dennis
authors.initials: D
authors.lastname: Grauer
authors.affiliation: University of Kansas School of Medicine, The University of Kansas Cancer Center, 2330 Shawnee Mission Parkway, Mail Stop 5003, Westwood, KS, 66205, USA. sabhyankar@kumc.edu.
authors.forename: Sunil
authors.initials: S
authors.lastname: Abhyankar
authors.affiliation: University of Kansas School of Medicine, The University of Kansas Cancer Center, 2330 Shawnee Mission Parkway, Mail Stop 5003, Westwood, KS, 66205, USA. oaljitawi@kumc.edu.
authors.forename: Omar
authors.initials: O
authors.lastname: Aljitawi
authors.affiliation: University of Kansas School of Medicine, The University of Kansas Cancer Center, 2330 Shawnee Mission Parkway, Mail Stop 5003, Westwood, KS, 66205, USA. sganguly@kumc.edu.
authors.forename: Siddhartha
authors.initials: S
authors.lastname: Ganguly
authors.affiliation: University of Kansas School of Medicine, The University of Kansas Cancer Center, 2330 Shawnee Mission Parkway, Mail Stop 5003, Westwood, KS, 66205, USA. jmcguirk@kumc.edu.
authors.forename: Joseph
authors.initials: J
authors.lastname: McGuirk
authors.affiliation: University of Kansas School of Medicine, The University of Kansas Cancer Center, 2330 Shawnee Mission Parkway, Mail Stop 5003, Westwood, KS, 66205, USA. asingh3@kumc.edu.
authors.forename: Anurag
authors.initials: A
authors.lastname: Singh
authors.affiliation: University of Kansas School of Medicine, The University of Kansas Cancer Center, 2330 Shawnee Mission Parkway, Mail Stop 5003, Westwood, KS, 66205, USA. tlin@kumc.edu.
authors.forename: Tara L
authors.initials: TL
authors.lastname: Lin
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D015992:Body Mass Index; D001835:Body Weight; D015331:Cohort Studies; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D054796:Drug Dosage Calculations; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D060828:Induction Chemotherapy; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications*; D050177:Overweight / Q000150:complications*; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D003561:Cytarabine
keywords: Actual body weight; Acute myeloid leukemia; Adjusted body weight; Induction chemotherapy; Obesity